Ionis
FDA approves AstraZeneca and Ionis’s Wainua
December 22, 2023Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua
AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …
Akcea and Ionis’ Waylivra nets CHMP approval in ultra-rare familial chylomicronaemia syndrome
March 5, 2019Manufacturing and Production, Sales and Marketing Akcea, FCS, Ionis, familial chylomicronemia syndrome, pharma, rare disease
Akcea Therapeutics and Ionis Pharmaceuticals have announced that their investigational therapy Waylivra (volanesorsen) has been recommended by the EMA’s Committee …
Ionis/Akcea’s ultra-rare disease drug rejected by FDA
August 28, 2018Manufacturing and Production, Sales and Marketing Akcea, FDA, Ionis, familial chylomicronemia syndrome, pharma, rare disease
The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary …
Biogen boosts pipeline with $1bn Ionis deal
April 23, 2018Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical
Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …
AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
Top Ten most popular articles on Pharmafile.com this week
December 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ionis, Sanofi, Teva, haemophilia, pharma, top ten
Just 10 days away from Christmas, and big news is still flowing in the industry. Sanofi remains embroiled in scandal …
Ionis scores huge breakthrough in Huntington’s, Roche licenses drug
December 12, 2017Manufacturing and Production, Research and Development Ionis, Roche, biotech, drugs, pharma, pharmaceutical
Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …
EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza
April 25, 2017Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy
Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …
Novartis and Ionis enter $1bn cardiovascular drug deal
January 6, 2017Medical Communications, Research and Development, Sales and Marketing Akcea, Akcea Therapeutics, Ionis, Ionis Pharmaceuticals, cardiovascular
Ionis Pharmaceuticals and one of its wholly-owned subsidiaries Akcea Therapeutics have entered into a partnership with Novartis worth potentially more …
Ionis achieves successful Phase 3 trial to treat rare diseases
December 19, 2016Manufacturing and Production, Research and Development Akcea, Ionis, rare disease
Ionis Pharmaceutial announced that the results of a Phase 3 trial into its treatment for hypertriglyceridemia met its primary endpoint. …
AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal
December 19, 2016Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS
AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …
Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint
November 7, 2016Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …
Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III
August 2, 2016Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …
ISIS Pharma changes name to Ionis to avoid ‘distracting’ militant association
December 21, 2015Sales and Marketing Ionis, Isis Pharmaceuticals, branding, marketing, rebrand
After months of discussion, ISIS Pharmaceuticals has changed its name to Ionis to free itself from the fear of confusion …
Latest content
